Processa Pharmaceuticals (PCSA)

• Market cap: $1.16M
• 1 day: -13.39%
• 5 days: -12.77%
• 1 month: -50.88%
• 3 months: -72.77%
• 6 months: -83.33%
• Year to date: -75.56%
• 1 year: -86.75%
• 5 years: -99.72%
• 10 years: -99.72%
• Sector: Healthcare
• Industry: Biotechnology

About: Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).

Employees: 13

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

200% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 1

32% more capital invested

Capital invested by funds: $66.5K [Q3] → $87.5K (+$21K) [Q4]

1.18% more ownership

Funds ownership: 1.49% [Q3] → 2.67% (+1.18%) [Q4]

0% more funds holding

Funds holding: 8 [Q3] → 8 (+0) [Q4]

0% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 2